Akebia Therapeutics, Inc.（股票代码：AKBA）已宣布，其候选药物Praliciguat在治疗局灶节段性肾小球硬化症（FSGS）的二期临床试验中，首位患者已完成首次给药。这一进展标志着该药物在针对这一罕见肾脏疾病的临床开发进程中迈出了关键一步。Praliciguat作为一种可溶性鸟苷酸环化酶激动剂，旨在通过改善肾脏微循环来缓解疾病进展。此次二期试验将评估其安全性、耐受性及初步疗效，为后续研究奠定基础。
Akebia Therapeutics, Inc.（股票代码：AKBA）已宣布，其候选药物Praliciguat在治疗局灶节段性肾小球硬化症（FSGS）的二期临床试验中，首位患者已完成首次给药。这一进展标志着该药物在针对这一罕见肾脏疾病的临床开发进程中迈出了关键一步。Praliciguat作为一种可溶性鸟苷酸环化酶激动剂，旨在通过改善肾脏微循环来缓解疾病进展。此次二期试验将评估其安全性、耐受性及初步疗效，为后续研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.